Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for Peptide Hybrid
Program will Focus on the Potential Treatment of Diabetes
14-Sep-2009
- India
Under the terms of the Development and Commercialization Agreement, Amylin will provide expertise in peptide hormone development, particularly in the area of phybrid technology, as well as metabolic disease therapeutics. Biocon will utilize its expertise in recombinant microbial expression to manufacture the compound and also leverage its experience in preclinical and clinical development of diabetes products.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
Emonta Pharma GmbH - Wien, Austria
Go to page
Allon Appoints Dr. Michael Gold Chief Medical Officer
Go to page
16th BioVaria honours SurvivX and QUASAR Therapeutics with Startup Pitch & Partner Awards - Among the GO-Bio initial and ForTra projects, Innovade, Cognisa and Mallia Therapeutics were selected as winners
Go to page
BioVisioN AG receives United States Patent for Peptide-Biomarker Discovery and Identification Technology
Go to page
Biophage signs a MOU with two US Companies for developing new generation of PDS® biosensors
Go to page
GATC refuses Frost & Sullivan Marketing Strategy Leadership Award
Go to page
Wyeth and Sienabiotech announce R.& D. collaboration in the field of neurodegenerative diseases - Agreement to maximise research synergies for new molecules active against Alzheimer's Disease
Go to page